Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3)

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) key facts

Used for
Enstilar ® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$1.41–$2.14 per gram (betamethasone dipropionate 0.05% · calcipotriene monohydrate 50 ug/g; NADAC)
Latest FDA recall
None listed

Sources: FDA label (October 18, 2021); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) used for?
The FDA-approved label (Enstilar, LEO Pharma Inc., October 18, 2021) says: “Enstilar ® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. Enstilar Foam is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis in patients 12 years and older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3)?
The “Adverse Reactions” section of the FDA label (Enstilar, LEO Pharma Inc., October 18, 2021) begins: “Adverse reactions reported in < 1% of subjects included application site irritation, application site pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, and exacerbation of psoriasis.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) have a boxed warning?
No. None of the 2 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3)?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3)?
2 companies list prescription products of Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) in the FDA NDC Directory, including LEO Pharma Inc. and Prasco Laboratories.

What Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Enstilar ® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. Enstilar Foam is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis in patients 12 years and older.

— FDA label: Enstilar, LEO Pharma Inc., effective October 18, 2021. Read the full label on DailyMed →

Label quoted: the one for the most common form (aerosol, foam, topical), Enstilar, LEO Pharma Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 2 FDA labels for this medicine have a boxed warning.

Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

Adverse reactions reported in < 1% of subjects included application site irritation, application site pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, and exacerbation of psoriasis.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma Inc. at 1-877-494-4536 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Conducted in Subjects 18 years and older with Psoriasis The rates of adverse reactions described below were from three randomized, multicenter, vehicle and/or active-controlled clinical trials in adult subjects with plaque psoriasis [see Clinical Studies (14)]. Subjects applied study product once daily for 4 weeks, and the median weekly dose of Enstilar Foam was 25 grams. Adverse reactions reported in <1% of adult subjects treated with Enstilar Foam included: application site irritation, application site pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, and exacerbation of psoriasis. Clinical Trials Conducted in Subjects 12 to 17 years with Psoriasis In one uncontrolled clinical trial, 106 subjects aged 12 to 17 years with plaque psoriasis of the scalp and body applied Enstilar Foam once daily for up to 4 weeks. The median weekly dose was 40 grams. Adverse reactions reported in <1% of adolescent subjects treated were acne, erythema, application site pain, and skin reactions [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.2)]. 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Postmarketing reports for local adverse reactions to Enstilar Foam included application site burning. Postmarketing reports for local adverse reactions to topical corticosteroids included atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection, and miliaria. Ophthalmic adverse reactions of cataracts, glaucoma, and increased intraocular pressure have been reported with the use of topical corticosteroids, including topical betamethasone products.

— FDA label: Enstilar, LEO Pharma Inc., effective October 18, 2021. Read the full label on DailyMed →

Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Shake can prior to using Enstilar Foam. Apply Enstilar Foam to affected areas once daily for up to 4 weeks. The maximum dose should not exceed 60 grams every 4 days. Rub in Enstilar Foam gently. Wash hands after applying the product. Discontinue Enstilar Foam when control is achieved. Enstilar Foam should not be used: with occlusive dressings unless directed by a healthcare provider. on the face, groin, or axillae, or if skin atrophy is present at the treatment site.

Read more of this section

Enstilar Foam is not for oral, ophthalmic, or intravaginal use. Shake before use. Apply Enstilar Foam to affected area(s) once daily for up to 4 weeks. Discontinue therapy when control is achieved. Do not use more than 60 grams every 4 days. (2) Do not use with occlusive dressings unless directed by a healthcare provider. (2) Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. (2) Not for oral, ophthalmic, or intravaginal use. (2)

— FDA label: Enstilar, LEO Pharma Inc., effective October 18, 2021. Read the full label on DailyMed →

Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3) in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Available data with Enstilar Foam are not sufficient to evaluate a drug-associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. Although there are no available data on use of the calcipotriene component in pregnant women, systemic exposure to calcipotriene after topical administration of Enstilar Foam is likely to be low [see Clinical Pharmacology (12.3)].

Read more of this section

Observational studies suggest an increased risk of having low birth weight infants with the maternal use of potent or super potent topical corticosteroids (see Data). Advise pregnant women that Enstilar ® Foam may increase the potential risk of having a low birth weight infant and to use Enstilar Foam on the smallest area of skin and for the shortest duration possible. In animal reproduction studies, oral administration of calcipotriene to pregnant rats during the period of organogenesis resulted in an increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs (see Data). Oral administration of calcipotriene to pregnant rabbits during the period of organogenesis had no apparent effects on embryo-fetal development. Subcutaneous administration of betamethasone dipropionate to pregnant rats and rabbits during the period of organogenesis resulted in fetal toxicity, including fetal deaths, reduced fetal weight, and fetal malformations (cleft palate and crooked or short tail) (see Data). The available data do not allow the calculation of relevant comparisons between the systemic exposures of calcipotriene and betamethasone dipropionate observed in animal studies to the systemic exposures that would be expected in humans after topical use of Enstilar Foam. The background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Available observational studies in pregnant women did not identify a drug-associated risk of major birth defects, preterm delivery, or fetal mortality with the use of topical corticosteroids of any potency. However, when the dispensed amount of potent or super potent topical corticosteroids exceeded 300 grams during the entire pregnancy, maternal use was associated with an increased risk of low birth weight in infants. Animal Data Embryo-fetal development studies with calcipotriene were performed by the oral route in rats and rabbits. Pregnant rats received dosages of 0, 6, 18, or 54 mcg/kg/day (0, 36, 108, and 324 mcg/m 2 /day, respectively) on days 6-15 of gestation (the period of organogenesis). There were no apparent effects on maternal survival, behavior, or body weight gain, no effects on litter parameters, and no effects on the incidence of major malformations in fetuses. Fetuses from dams dosed at 54 mcg/kg/day exhibited a significantly increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs.

— FDA label: Enstilar, LEO Pharma Inc., effective October 18, 2021. This is part of the section. Read the full label on DailyMed →

Forms and how it is given

Dosage formsAerosol, foam · Ointment
RouteTopical
Prescription products2 in the FDA NDC Directory
Brand namesEnstilar

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Calcipotriene and betamethasone dipropionate (betamethasone dipropionate / calcipotriene monohydrate) (3), by strength and form
Strength and formGeneric or brandPharmacies pay
betamethasone dipropionate 0.05% · calcipotriene monohydrate 50 ug/g
aerosol, foam
Brand: Enstilar $21.80–$21.82 per gram
2 packages, lowest to highest
betamethasone dipropionate 0.05% · calcipotriene monohydrate 50 ug/g
ointment
Generic $1.41–$2.14 per gram
2 packages, lowest to highest

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA021852
TACLONEX
Leo Pharma AsJanuary 9, 2006 10, latest December 21, 2018
2018: Labeling · 2014: Efficacy · 2014: Labeling
NDA207589
ENSTILAR
Leo Pharma AsOctober 16, 2015 7, latest August 6, 2021
2021: Labeling · 2020: Efficacy · 2019: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)388525, 1716094, 1716099
SPL set ID of the quoted labeld1193df2-d53f-4342-bd9d-d9cba7c89709
FDA labels (SPL)2
FDA applicationsNDA021852, NDA207589
Active ingredients (FDA)BETAMETHASONE DIPROPIONATE / CALCIPOTRIENE MONOHYDRATE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Enstilar, LEO Pharma Inc., effective October 18, 2021; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers